An Open-Label, Worldwide, Treatment Use Study to Provide Ezetimibe 10 Mg/Day to Patients With Homozygous Familial Hypercholesterolemia or Homozygous Sitosterolemia.

Trial Profile

An Open-Label, Worldwide, Treatment Use Study to Provide Ezetimibe 10 Mg/Day to Patients With Homozygous Familial Hypercholesterolemia or Homozygous Sitosterolemia.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Ezetimibe (Primary)
  • Indications Hyperlipoproteinaemia type II; Sitosterolaemia
  • Focus Adverse reactions; Registrational
  • Acronyms COMPLETED
  • Sponsors Merck & Co
  • Most Recent Events

    • 21 Feb 2012 Actual patient number (49) added as reported by ClinicalTrials.gov.
    • 21 Feb 2012 Planned end date (Jan 2006) added as reported by ClinicalTrials.gov.
    • 21 Feb 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top